CSL (Melbourne, Australia) At the back of a building in Melbourne's northern outskirts is a long, narrow room roughly the area of a tennis court.
Technicians and operators — fully decked out in protective onesies, gloves, goggles, hairnets and masks — bustle about, tending to a vast array of gleaming stainless steel equipment and what looks like kilometres of plastic tubing. There are people here at all hours, too — it's a 24/7 operation. That's because this room, part of CSL's Broadmeadows plant, is where 50 million doses of the Oxford-AstraZeneca COVID-19 vaccine will be grown. SK Bioscience (South Korea) SK Bioscience made a major score last week when it unveiled a lucrative coronavirus vaccine deal with Novavax.
Just six days later, SK announced a plan that ups the ante—to the tune of $900 million. When the contract drug manufacturer launches an initial public offering on the Korea Exchange next month, it expects to raise that amount, CEO Ahn Jae-yong said in a news conference, and it has big plans for spending it. The company, a subsidiary of the SK Group, plans to invest $360 million in domestic facilities and $90 million on expanding overseas. It also has earmarked $180 million for R&D in a joint effort with French drugmaker Sanofi to develop a pneumococcal COVID-19 vaccine. Cobra Biologics. Providing large scale manufacturing capacity for AZD1222 Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.
The production agreement is part of AstraZeneca’s recently announced in-licensed programme with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit during the COVID-19 pandemic. Cobra hit the ground running with AstraZeneca and other manufacturing organisations to provide large scale manufacturing capacity of AZD1222 vaccine. Cobra, along with other consortium members, will be manufacturing the vaccine with first deliveries to begin in the UK in September 2020. Wockhardt (UK)
Siam Bioscience (Siam Bioscience) Siam Bioscience was chosen by AstraZeneca after a detailed assessment and comparison against other institutions proposed by Thailand, according to the National Vaccine Institute (NVI).
Dr. Nakorn Premsri, the director of the NVI, said that AstraZeneca was the one who told Thailand that it would be better to reserve vaccines from them because they will be manufactured in Thailand. Dr. Nakorn added that the decision to transfer technology was made well before Thailand decided to procure vaccines from AstraZeneca. Shenzhen Kangtai. mAbxience (Argentina) mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America.
Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and filling process. The agreement with AstraZeneca, and financed mainly by the Carlos Slim Foundation,will provide more than 200 million doses of the vaccine to be supplied to all Latin American countries, except Brazil.
AstraZeneca is one of the largest drug manufacturers in the world, and in partnership with the University of Oxford, has achieved highly promising results with this vaccine. Being selected as a partner for such a crucial project clearly evidences that mAbxience is a top-level, trusted partner with extremely solid quality standards. JCR Pharma (Japan) Emergent Biosolutions (Baltimore, USA) Emergent will provide contract development and manufacturing services beginning in 2020 to produce drug substance at large scale for commercial supply Agreement is valued at approximately through 2021 and brings the total AstraZeneca commitment to Parties may enter into additional commercial manufacturing commitments as the candidate progresses over three years through Emergent’s flexible capacity deployment model , (GLOBE NEWSWIRE) -- (NYSE:EBS) today announced that it has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
The agreement is valued at approximately through 2021 and follows an contract in June for development services, performance and process qualification, raw materials and an initial capacity reservation. About is a global life sciences company whose mission is to protect and enhance life. Bio-Manguinhos/Fiocruz (Brazil)
The Oswaldo Cruz Foundation (Fiocruz) will sign an agreement with pharmaceutical company AstraZeneca for the acquisition of batches and transference of technology regarding the Covid-19 vaccine developed by the University of Oxford.
The agreement will be the result of the cooperation between the Brazilian government and the pharmaceutic company, announced last Saturday, June 27, by the Ministry of Health. Halix (Netherlands) Accepting cookies makes our website easier to navigate, lets you find what you are looking for faster and helps us show you information that is more likely to be of interest to you.
Do you accept and consent to cookies? Please choose one of our cookie options: Essential: Remember your cookie permission settingEssential: Allow session cookiesEssential: Gather information you input into a contact forms newsletter and other forms across all pagesEssential: Keep track of what you input in a shopping cartEssential: Authenticate that you are logged into your user accountEssential: Remember language version you selected. Novasep (Seneffe, Belgium) Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce that it has now signed a multi-year Master Supply and Development Agreement with AstraZeneca to support large-scale production of the active substance of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222.
This new contract follows the initial agreement signed between AstraZeneca and Novasep Belgium on June 14th in the context of the Inclusive Alliance for Vaccines (IAV), whose members are France, Germany, Italy and the Netherlands. The production of the vaccine candidate active substance under this supply agreement will be carried out at Novasep’s site located in Seneffe, Belgium which expects to increase its workforce from 280 to close to 400 by 2021 to support this project.
Dr. Contact presseBrunswick GroupAgnès Catineau / Orianne Bornand / Solène DeguetNovasep@brunswickgroup.com+33 7 78 50 95 46 English French German. Medimmune Pharma (Netherlands) Thermo Fisher Scientific (Belgium) R-Pharm (Illertissen, Germany) Serum institute of India (Pune)